Assessing the analytic validity of molecular testing for Huntington disease using data from an external proficiency testing survey

被引:13
作者
Palomaki, Glenn E. [1 ,2 ]
Richards, C. Sue [3 ]
机构
[1] Brown Univ, Women & Infants Hosp, Dept Pathol & Lab Med, Providence, RI 02912 USA
[2] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[3] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA
关键词
analytic validity; external proficiency testing; Huntington disease; quality assurance;
D O I
10.1038/gim.0b013e3182310bb5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Documenting high analytic validity of the molecular diagnostic test for Huntington disease is important because of counseling implications. This dominantly inherited adult onset disorder (prevalence of three or more per 100,000) is characterized by chorea, ataxia, and personality changes. The molecular basis is excessive CAG repeats in the HTT gene. Methods: External proficiency testing survey results for Huntington disease were extracted (2003-2010). Analytic interpretations and CAG repeat lengths were compared with published performance criteria. Results: Between 2008 and 2010, 33 US participating laboratories reported clinical test interpretations. Analytic validity was high (sensitivity: 99.5%, 95% confidence interval: 97.1-99.9%; specificity: 99.2%, 95% confidence interval: 97.1-99.9%). Repeat length errors occurred in 2.6% (95% confidence interval: 1.8-3.8%) of 1,060 allelic challenges, with most being minor or from a single participant. Past performance (2003-2007) was similar. The 23 international participants had more total repeat length errors (17.5%, 95% confidence interval: 14.6-20.7%). Further analyses indicated that assessment criteria can be relaxed without jeopardizing analytic validity. Conclusion: Analytic validity is high for Huntington disease testing among US laboratories. International survey participants had lower analytic validity and a higher proportion of poorly performing laboratories. The reasons for this are unclear.
引用
收藏
页码:69 / 75
页数:7
相关论文
共 10 条
[1]  
*AM COLL MED GEN, 2006, STAND GUID CLIN GEN
[2]  
[Anonymous], GENETESTS
[3]   A new method for accurate assessment of DNA quality after bisulfite treatment [J].
Ehrich, Mathias ;
Zoll, Scott ;
Sur, Sudipto ;
van den Boom, Dirk .
NUCLEIC ACIDS RESEARCH, 2007, 35 (05)
[4]  
Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
[5]  
Hayden M, 1996, EMERY RIMOINS PRINCI, P2203
[6]   Oversight of US genetic testing laboratories [J].
Hudson, Kathy L. ;
Murphy, Juli A. ;
Kaufman, David J. ;
Javitt, Gail H. ;
Katsanis, Sara H. ;
Scott, Joan .
NATURE BIOTECHNOLOGY, 2006, 24 (09) :1083-1090
[7]   Genetic testing oversight [J].
Hudson, Kathy L. .
SCIENCE, 2006, 313 (5795) :1853-1853
[8]   Development of genomic reference materials for Huntington disease genetic testing [J].
Kalman, Lisa ;
Johnson, Monique A. ;
Beck, Jeanne ;
Berry-Kravis, Elizabeth ;
Buller, Arlene ;
Casey, Brett ;
Feldman, Gerald L. ;
Handsfield, James ;
Jakupciak, John P. ;
Maragh, Samantha ;
Matteson, Karla ;
Muralidharan, Kasinathan ;
Richie, Kristy L. ;
Rohlfs, Elizabeth M. ;
Schaefer, Frederick ;
Sellers, Tina ;
Spector, Elaine ;
Richards, C. Sue .
GENETICS IN MEDICINE, 2007, 9 (10) :719-723
[9]  
Potter Nicholas T, 2004, Genet Med, V6, P61, DOI 10.1097/01.GIM.0000106165.74751.15
[10]   To know or not to know: A review of behaviour and suicidal ideation in preclinical Huntington's disease [J].
Wahlin, Tarja-Brita Robins .
PATIENT EDUCATION AND COUNSELING, 2007, 65 (03) :279-287